1. Hematopoietic cell transplantation for Diamond Blackfan anemia: A report from the Pediatric Group of the Brazilian Bone Marrow Transplantation Society
- Author
-
Victor Zecchin, Mair de Souza, Gisele Loth, Alessandra Gomes, Mary E.D. Flowers, Leonardo Javier Arcuri, Ana Cristina Vieira, Cilmara Kuwahara, Vergilio A.R. Colturato, Antonio Vaz de Macedo, Ana Luiza Melo Rodrigues, Rodolfo Calixto, Luiz Guilherme Darrigo, Juliana Ruiz Fernandes, Lisandro Ribeiro, Adriana Seber, Carmem Bonfim, Rita de Cássia Barbosa Tavares, Vanderson Rocha, and Ricardo Pasquini
- Subjects
Male ,medicine.medical_specialty ,Anemia ,medicine.medical_treatment ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,Human leukocyte antigen ,Severity of Illness Index ,03 medical and health sciences ,0302 clinical medicine ,HLA Antigens ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Sibling ,Diamond–Blackfan anemia ,Child ,Anemia, Diamond-Blackfan ,Bone Marrow Transplantation ,Retrospective Studies ,business.industry ,Histocompatibility Testing ,Siblings ,Hematopoietic Stem Cell Transplantation ,Disease Management ,Infant ,Hematology ,General Medicine ,medicine.disease ,Transplantation ,surgical procedures, operative ,medicine.anatomical_structure ,Child, Preschool ,Health Care Surveys ,030220 oncology & carcinogenesis ,Cohort ,Female ,Bone marrow ,Unrelated Donors ,business ,Brazil ,030215 immunology - Abstract
Objectives The aim of this study was to analyze the outcomes of children with Diamond-Blackfan anemia (DBA) treated in Brazil with hematopoietic cell transplantation (HCT). Methods We performed a retrospective analysis of 44 pediatrics patients transplanted between 1990 and 2018. The median age of patients was 5 years, and 57% were male. Twenty-five received their first HCT from an HLA-matched sibling donor (MSD), 12 from a HLA matched unrelated bone marrow donor (MUD 10/10, n = 12) and 7 other HLA mismatched donors (MMD). Results After a median follow-up of 4 years, estimate 5-year overall survival (OS) for the entire cohort was 70%, 80% for MSD group, 73% for MUD, and 29% for MMD. Thirty-eight out of the 44 evaluable patients engrafted successfully. Primary and secondary graft failure was observed in five and three patients, respectively. Rates of grade II-IV and III-IV acute graft-versus-host disease (aGVHD) were 25% and 18%, respectively. Nine patients developed chronic GVHD (cGVHD). Conclusion Overall survival rates observed after HLA matched donors transplant for DBA were comparable to those reported from higher-income countries and international registries.
- Published
- 2020
- Full Text
- View/download PDF